ArticleThe Journal of biological chemistry2020
A drug-resistant β-lactamase variant changes the conformation of its active-site proton shuttle to alter substrate specificity and inhibitor potency.
Open access · hybridAbstract read
In one paragraph
Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 32% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Cefdinir binding to a class A β-lactamase revealed by serial cryo-crystallography.Acta crystallographica. Section D, Structural biology · 2026Article
- Structural perspectives on clinical β-lactamase inhibitors: From mechanism to resistance.Journal of microbiology (Seoul, Korea) · 2026Review
- Structural comparison of substrate-binding pockets of serine β-lactamases in classes A, C, and D.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Binding mode of Isoxazolyl Penicillins to a Class-A β-lactamase at ambient conditions.Communications chemistry · 2025Article
- Network of epistatic interactions in an enzyme active site revealed by large-scale deep mutational scanning.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Toward physics-based precision medicine: Exploiting protein dynamics to design new therapeutics and interpret variants.Protein science : a publication of the Protein Society · 2024Review
- Investigating the antibacterial potential of thiophene derivatives against wound infections: a combined DFT, molecular docking, and ADMET study targetingIn silico pharmacology · 2024Article
- Millisecond cryo-trapping by the spitrobot crystal plunger simplifies time-resolved crystallography.Nature communications · 2023Article
- Mapping the determinants of catalysis and substrate specificity of the antibiotic resistance enzyme CTX-M β-lactamase.Communications biology · 2023Article
- An active site loop toggles between conformations to control antibiotic hydrolysis and inhibition potency for CTX-M β-lactamase drug-resistance enzymes.Nature communications · 2022Article
- Klebsiella pneumoniae Carbapenemase Variants Resistant to Ceftazidime-Avibactam: an Evolutionary Overview.Antimicrobial agents and chemotherapy · 2022Review
- Excreted Antibiotics May Be Key to Emergence of Increasingly Efficient Antibiotic Resistance in Food Animal Production.Applied and environmental microbiology · 2022Article
- Three new inhibitors of class A β-lactamases evaluated by molecular docking and dynamics simulations methods: relebactam, enmetazobactam, and QPX7728.Journal of molecular modeling · 2022Article
- Two β-Lactamase Variants with Reduced Clavulanic Acid Inhibition Display Different Millisecond Dynamics.Antimicrobial agents and chemotherapy · 2021Article
- Local interactions with the Glu166 base and the conformation of an active site loop play key roles in carbapenem hydrolysis by the KPC-2 β-lactamase.The Journal of biological chemistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Victoria SoeungDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas, USA.
Shuo LuDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas, USA.
Liya HuDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.
Allison JudgeDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA.
Banumathi SankaranDepartment of Molecular Biophysics and Integrated Bioimaging, Berkeley Center for Structural Biology, Lawrence Berkeley National Laboratory, Berkeley, California, USA.
B V Venkataram PrasadDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Timothy PalzkillDepartment of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas, USA; Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas, USA; Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA. Electronic address: timothyp@bcm.edu.
Baylor College of Medicine · USLawrence Berkeley National Laboratory · US
Funding
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI PAUL David ADAMS, Gregory L Hura · 2017 to 2026
$28.6MBETA-LACTAMASE MUTATIONS IN ANTIBIOTIC RESISTANCER01AI032956 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI Timothy Palzkill · 1992 to 2026
$6.5MBeta Lactamase Mutations in Antibiotic ResistanceR37AI032956 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI PALZKILL, TIMOTHY · 2001 to 2010
$3.3MTraining Interdisciplinary Pharmacology ScientistsT32GM120011 · NIGMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI DESSAUER, CARMEN W. · 2016 to 2020
$1.0MBeta Lactamase Mutations in Antibiotic ResistanceR56AI032956 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI PALZKILL, TIMOTHY · 2016 to 2016
$394kNIAID NIH HHS R01 AI032956NIAID NIH HHS R37 AI032956NIAID NIH HHS R56 AI032956NIGMS NIH HHS P30 GM124169NIGMS NIH HHS T32 GM120011
Abstract
Lys
Indexed as
MutationProtonsAnti-Bacterial Agentsbeta-Lactamase Inhibitorsbeta-Lactamasesbeta-Lactam ResistanceCatalytic DomainEscherichia coliMutagenesis, Site-DirectedProtein ConformationSubstrate SpecificityAnti-Bacterial Agentsbeta-lactamase CTX-M-14beta-Lactamase Inhibitorsbeta-LactamasesProtonsantibiotic resistanceantibioticsbeta-lactamaseenzyme inhibitorenzyme kineticsenzyme structure
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.